Analyst: Chinese reforms will impact sales and earnings at Novo Nordisk

Chinese healthcare reforms, meant to reduce healthcare expenses, could negatively affect Novo Nordisk, assesses Jyske Bank analyst, lowering forecasts for the company's revenue and earnings.
Photo: Simon Fals
Photo: Simon Fals

Danish Jyske Bank reduces its 2022 revenue and earnings estimates for Novo Nordisk by a respective 3.1 and 4.8 percent as a consequence of China's healthcare reform efforts to keep costs down, writes Chief Analyst at Jyske Bank Henrik Hallengreen Laustsen. The analyst has the recommendation "hold" with a share price target of DKK 645 for Novo Nordisk.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading